Serotonin transporter (SERT) and translocator protein (TSPO) expression in the obese ob/ob mouse by Giannaccini, Gino et al.
RESEARCH ARTICLE Open Access
Serotonin transporter (SERT) and translocator protein
(TSPO) expression in the obese ob/ob mouse
Gino Giannaccini
1*, Laura Betti
1, Lionella Palego
1, Andrea Pirone
2, Lara Schmid
1, Mario Lanza
1, Laura Fabbrini
1,
Caterina Pelosini
3, Margherita Maffei
3, Ferruccio Santini
3, Aldo Pinchera
3, Antonio Lucacchini
1
Abstract
Background: An ever growing body of evidences is emerging concerning metabolism hormones,
neurotransmitters or stress-related biomarkers as effective modulators of eating behavior and body weight in
mammals. The present study sought at examining the density and affinity of two proteins related to
neurotransmission and cell metabolism, the serotonin transporter SERT and the cholesterol import-benzodiazepine
site TSPO (translocator protein), in a rodent leptin-lacking mutant, the obese ob/ob mouse. Binding studies were
thus carried out in brain or peripheral tissues, blood platelets (SERT) and kidneys (TSPO), of ob/ob and WT mice
supplied with a standard diet, using the selective radiochemical ligands [
3H]-paroxetine and [
3H]-PK11195.
Results: We observed comparable SERT number or affinity in brain and platelets of ob/ob and WT mice, whilst a
significantly higher [
3H]-PK11195 density was reported in the brain of ob/ob animals. TSPO binding parameters
were similar in the kidneys of all tested mice. By [
3H]-PK11195 autoradiography of coronal hypothalamic-
hippocampal sections, an increased TSPO signal was detected in the dentate gyrus (hippocampus) and choroids
plexus of ob/ob mice, without appreciable changes in the cortex or hypothalamic-thalamic regions.
Conclusions: These findings show that TSPO expression is up-regulated in cerebral regions of ob/ob leptin-
deficient mice, suggesting a role of the translocator protein in leptin-dependent CNS trophism and metabolism.
Unchanged SERT in mutant mice is discussed herein in the context of previous literature as the forerunner to a
deeper biochemical investigation.
Background
The mechanisms of action of appetite hormones and
related networks operating on body weight control have
not been entirely established in mammals; the study of
these pathways in models of mutant rodents, is contri-
buting to elucidate the issue. In particular, the obese ob/
ob mouse, mutant for the leptin (OB hormone) gene, is
currently used to evaluate the pathogenesis of human
obesity and type 2 diabetes: it lacks the functional leptin,
develops hyperphagia, insulin resistance, hyperglycemia
and hypercholesterolemia together altered immune
response, impaired locomotor activity and fertility [1].
Leptin release from adipose cells is stimulated by insulin
and glucocorticoids while counter-regulatory hormones
inhibit its secretion [2].
In the hypothalamus, leptin exerts a double action: it
up-regulates the release of anorexigenic neuropeptides
as melanotropic hormone (a-MSH), CART (cocaine/
amphetamine-regulated transcript) and CRH (corticotro-
pin-releasing hormone) while inhibiting secretion of
orexigenic neuropeptide Y (NPY), MCH (melanin-con-
centrating hormone), orexins, and AGRP (agouti-related
peptide), all signals that, at the opposite, increases appe-
tite and reduces energy consumption. Thus, ob/ob mice
present a significant impairment of leptin-dependent
hypothalamic pathways, accompanied by adrenal hyper-
trophy and increased corticosteroid secretion during
diurnal rhythms [3,4]. The use of ob/ob animals has
shown the involvement of catecholamines and serotonin
(5-HT) in the leptin-deficient syndrome: in mutant ani-
mals, dopaminergic agonists reduce food intake and
restrain metabolic dysfunctions, while SSRI antidepres-
sant treatment decreases hyperphagia and hyperglycemia
[1]. Some authors have observed a reduced expression
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nuclei of ob/ob animals accompanied by an altered loco-
motor activity [5]. Despite all these evidences, to our
knowledge, there are still controversial opinions con-
cerning the existence of interactions between leptin,
5-HT transmission and stress signals.
The aim of this study was therefore to investigate the
expression of two pivotal proteins involved in 5-HT
transmission and metabolism, SERT and the transloca-
tor protein (TSPO), in central and peripheral tissues of
ob/ob mice in comparison with wild-type (WT) animals.
SERT was evaluated given th a ti tm o d u l a t e st h e5 - H T
re-uptake inside serotonergic neurons, a key mechanism
permitting the activation/desensitization of 5-HT recep-
tors within the synaptic cleft. SERT is also localized in
periphery where it regulates platelet aggregation, gut
peristalsis and immune response. An altered SERT has
been reported in several complex human disorders, such
as psychiatric diseases, pain and eating disturbances [6].
Density and affinity values of the TSPO protein were
instead investigated as potential markers of stress-
response and cholesterol metabolism in ob/ob obese
mice. The TSPO protein is in fact the mitochondrial
import of cholesterol with binding sites for benzodiaze-
pines [7,8], also implicated in steroidogenesis [7-9]. The
TSPO molecular complex is prevalently located on the
mitochondrial membrane and is formed by: the main
subunit, the isoquinolinic binding protein (18 KDa,
identified as TSPO), the benzodiazepine binding portion
VDAC (32 KDa, voltage dependent anionic channel)
and the adenine nucleotide translocator ANT, which is
also a target for benzodiazepines. Associated compo-
nents of the complex are StAR (steroidogenesis acute
regulatory) and PAP7 (associated protein 7) proteins,
implicated in the steroidogenesis process [8]. Nonethe-
less, the precise function of TSPO is unknown [10].
TSPO has been indeed related to a variety of biological
functions and processes, such as protection against reac-
tive oxygen species, regulation of cell apoptosis, immu-
nity and porphyrin transport [9]. Moreover, TSPO
expression has been found changed in several diseases
and pathological conditions [9], including psychiatric
diseases and fibromyalgia where altered densities of
both SERT and TSPO have been reported [11-13].
SERT and TSPO proteins were thus appraised by
means of binding assays carried out in either neuronal
or peripheral districts of ob/ob and WT mice. SERT was
measured through the high-affinity SSRI ligand [
3H]-
paroxetine on brain and platelets, whereas TSPO was
assessed by the isoquinilinic compound [
3H]-PK11195
on brain and kidney. We also performed autoradio-
graphic studies on limbic-hypothalamic coronal sections
of mouse brain. Some previous works have in fact
shown changes in SERT and 5-HT receptor subtypes at
the level of the hypothalamus and limbic areas of mice
fatten by a palatable diet [14,15]. Plasma chemical ana-
lyses were carried out in animals to evaluate their meta-
bolic state.
Results
Analysis of blood chemical parameters
A ss h o w ni nT a b l e1 ,ob/ob mice had higher levels of
total cholesterol, glucose and High-Density-Lipoprotein
( H D L )i nc o m p a r i s o nw i t hW Tm i c e .C o n c e r n i n gt h e
other blood parameters examined, no relevant between-
genotype difference was reported. g-GT enzyme activity
did not exceed 40 U lt
-1 (0-40 U lt
-1)i nob/ob and
mutant animals, indicating a normal hepatic function in
all mice.
[
3H]-paroxetine and [
3H]-PK11195 binding parameters
[
3H]-paroxetine Scatchard analysis revealed a single
population of high-affinity binding sites in all membrane
preparations. [
3H]-paroxetine equilibrium binding
experiments (mean ± SD, 4 separate experiments in
duplicate), showed no significant difference in either
SERT density (Bmax, fmol/mg protein) or affinity (KD,
nM) in both brain and platelets of ob/ob vs WT animals
(Table 2).
[
3H]-PK11195 binding Scatchard analysis also fitted
with a single population of high-affinity sites in brain
and kidneys. As shown in Table 3, no variation of [
3H]-
PK11195 binding affinity (KD,n M )w a so b s e r v e di n
brain and kidneys (mean ± SD, 4 separate experiments
performed in duplicate) of different animals, whilst a
significant increased Bmax was observed in the ob/ob
brain (p < 0.05). Kidney Bmax resulted unchanged from
comparison analysis of the two genotypes. Figure 1
depicts a representative linear transformation Scatchard,
analysis obtained in brain membranes from ob/ob and
WT mice, displaying an increased TSPO number in
mutant animals.
Autoradiography of brain coronal sections
Figure 2 depicts [
3H]-PK11195 and [
3H]-paroxetine
autoradiography on coronal brain sections carried out at
the hypothalamic-hippocampal level. TSPO binding sites
Table 1 Blood chemical parameters
(a) in mice
Chemical parameters ob/ob WT
Glucose 158 ± 18 61 ± 6
Total Cholesterol > 450 226 ± 19
High Density Cholesterol 87 ± 7 < 50
Triglycerides 27 ± 2 31 ± 4
Calcium 6.8 ± 0.4 6.1 ± 0.3
(a): Data are presented as mean ± SD (mg dl
-1) of measures carried out in
plasma samples separated from n = 3 ob/ob and n = 3 WT animals as
indicated in the Methods section.
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3H]-PK11195 (Figure 2.a,b) resulted unevenly
distributed in these brain regions, with the highest
expression in the cerebral cortex and hypothalamus.
[
3H]-PK11195 density signal was found increased in the
dentate gyrus (hippocampus) of ob/ob mice (Figure 2b),
together a binding raise in correspondence of peri-ven-
tricular areas, at the level of the choroids plexus, espe-
cially that surrounding the dorsal third ventricle.
Figure 2 (c,d) also shows brain sections labeled by
[
3H]-paroxetine. These sections differed for about 55
μmf r o mt h e[
3H]-PK11195 ones (Figure 2.a,b), display-
ing a quite diffuse SERT labeling in cortex, hippocam-
pus, hypothalamus and thalamus. Despite some
decreased signal in the ob/ob cortex (Figure 2.d) vs. the
WT one (Figure 2.c), these changes were not significant.
Discussion
Since many years, the ob/ob mouse is conceived as a sui-
table experimental model for studying neuropeptide sub-
strates and metabolic pathways implicated in human
obesity and type 2 diabetes [1]: these rodents bear a non-
sense mutation in the coding region of the leptin gene
causing the lack of secretion of a functional peptide. An
important aspect should be considered when using this
mutant model: human obesity is rarely due to a single
gene mutation [4] and obese humans prevalently present
high circulating levels of leptin [16] together desensitized,
leptin-resistant pathways; by contrast, ob/ob mice are
defective in leptin production. Differences between these
two conditions have not been still elucidated at the bio-
chemical level. The ob/ob syndrome can be reversed by
exogenous administration of leptin or by leptin gene
transfection [1], proving that leptin receptors and net-
works are functional. On the other side, the study of ob/
ob mice permits to dissect leptin-dependent neuroendo-
crine loops, involved in appetite control and energy bal-
ance dysfunctions. Indeed, as already mentioned, leptin
pathways, co-modulation or connection with corticotro-
pin releasing factor (CRF), NPY, a-MSH and neurotrans-
mitter systems have not been fully characterized [2].
Specifically, energy expenditure balance and feeding
behavior are regulated by redundant pathways: monoa-
mines and leptin are both able to modulate food intake
at the hypothalamic levels, but it is not precisely known
if and how these signal molecules interact [17]. Some
authors also consider leptin a signal evolved to prevent
starvation rather than food plenty [18]. Beside alterations
of glucose metabolism, another important feature of the
ob/ob syndrome is the increased blood cholesterol in
mutant animals. Cholesterol is the precursor of steroido-
genesis, being a main, high-affinity ligand for the benzo-
diazepine site-translocator protein TSPO [7,9]. Reduced
cholesterol levels have been evidenced inside macro-
phages of ob/ob mice, along with a diminished capacity
in inflammatory response [19], supporting metabolic and
hormonal cross-talks between immune response, inflam-
mation and body weight signals [20,21]. Interestingly,
platelet TSPO and SERT densities have been found
altered in fibromyalgia [12,13], panic disorders [11,22]
and suicide attempters [23,24]. This prompted us to pre-
liminary assess the equilibrium-binding parameters of
SERT and TSPO proteins, either in brain or high expres-
sion peripheral tissues, circulating platelets and kidneys,
Table 2 [
3H]-paroxetine binding parameters
(a) in mouse
membranes
Brain: Kd (nM) Bmax (fmol/mg protein)
ob/ob Mutant 0.1 ± 0.01 368 ± 17.5
Wild Type 0.09 ± 0.01 341 ± 18.0
Platelets: Kd (nM) Bmax (fmol/mg protein)
ob/ob Mutant 0.09 ± 0.008 18680 ± 2278
Wild Type 0.08 ± 0.01 14830 ± 1722
(a): Data are presented as mean ± SD of n = 4 separate experiments in brain
or platelet membrane preparations carried out in ob/ob and WT animals as
indicated in the Methods section.
Table 3 [
3H]-PK11195 binding parameters
(a) in mouse
membranes
Brain: Kd (nM) Bmax (fmol/mg protein)
ob/ob Mutant 1.75 ± 0.3 403.5 ± 12.6 (*)
Wild Type 1.8 ± 0.2 329.5 ± 16.0
Kidney: Kd (nM) Bmax (fmol/mg protein)
ob/ob Mutant 1.9 ± 0.2 19550 ± 1180
Wild Type 2.0 ± 0.3 20260 ± 2017
(a): Data are presented as mean ± SD of n = 4 separate experiments in brain
and kidney membrane preparations carried out in ob/ob and WT animals as
indicated in the Methods sections. (*): Student t-test, p < 0.05.
Figure 1 [
3H]-PK11195 binding assay in WT and ob/ob brain
membranes. Scatchard lines are representative of [
3H]PK11195
saturation binding of 4 separate experiments carried out in brain
membranes of obese ob/ob (□) and WT (■) mice.
Giannaccini et al. BMC Neuroscience 2011, 12:18
http://www.biomedcentral.com/1471-2202/12/18
Page 3 of 8of ob/ob mice: to our knowledge, this is the first study
that simultaneously evaluates SERT and TSPO expres-
sion in distinct anatomical district of a rodent genetic
model of obesity.
Prior to SERT and TSPO analyses, blood chemical
parameters were determined in ob/ob and WT animals
to monitor cell metabolism: higher total cholesterol and
glucose concentrations were observed in mutant vs. WT
animals, according to data provided by the commercial
source. Blood levels of the g-GT enzyme were low in
ob/ob and WT mice, indicating the absence of hepatic
alterations. Moreover, ob/ob mice presented similar cir-
culating triglyceride or calcium levels to those measured
in WT animals. Concerning binding results, no difference
of SERT density or affinity was reported in brain and pla-
telets of ob/ob and control mice. Also, [
3H]-paroxetine
autoradiographic sections showed no appreciable binding
differences between animals. This finding could signify
that leptin-dependent pathways are altered in ob/ob mice
without affecting 5-HT transmission. On the other hand,
the fact that ob/ob mice show no changes in SERT den-
sity or affinity (present results) but a reduced SERT
mRNA [5] is intriguing. Since leptin has been found able
to decrease SERT binding sites in the rat brain [25], the
ob/ob mouse could maintain the capacity at counteract-
ing the decrease of SERT transcripts at the protein level,
in the absence of SERT (or SERT-related) gene muta-
tions. In fact, SERT underlies posttranslational regula-
tion, trafficking or protein inactivation causing a
differential distribution within cell compartments and/or
discrepancies between mRNA and protein expression, as
reported during megakaryoblastic differentiation [26].
Figure 2 [
3H]-PK11195 (a,b) and [
3H]-paroxetine (c,d) autoradiography in coronal hypothalamic-hippocampal sections of WT and ob/
ob brain. The increased signal corresponding to [
3H]-PK11195 binding in sections of ob/ob mice is indicated by arrows (hippocampal region
and choroids plexus-third ventricle). cc: cerebral cortex; hi: hippocampal region; hy: hypothalamus; th: thalamus.
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responsiveness together a modified SERT reserve/func-
tion (uptake), without significant differences in binding
sites. A deeper biochemical analysis of SERT should be
therefore carried out, including flow cytofluorimetry,
immunoprecipitation, gene expression, proteomic-
functional (uptake) studies, in the context of 5-HT (or
other monoamine) levels in blood and tissues of these
animals. Concerning TSPO binding results, this protein
was found increased in the ob/ob mouse brain while
being similar in kidneys of mutant and WT animals. The
[
3H]PK11195 autoradiography of hippocampal-hypotha-
lamic sections has revealed an up-regulation of TSPO
d e n s i t yi nt w ob r a i nr e g i o n so fob/ob mice, the dentate
gyrus of hippocampus and choroids plexus, indicating
that TSPO number variations in ob/ob mouse brain are
region-dependent. These results also underline that lep-
tin chronic deficiency affects brain protein patterns.
The interpretation of our TSPO finding is difficult. In
fact, to date, the precise role of TSPO within CNS is not
understood. A brain region-specific regulatory mechanism
in response to hypercholesterolemia and hyperglycemia
could be active in these animals. Brain TSPO is mainly
localized on glial cells and can be modulated by protein
kinase C signaling [7] and the cAMP-protein kinase A
pathway [9], activated by G-protein coupled receptors,
including, therefore, metabotropic 5-HT receptor sub-
types. In hippocampus and choroids plexus there could be
an unbalance of regulatory signaling cascades, resulting in
the enhancement of TSPO number. This could depend
upon many factors, such as different receptor sub-type
localization and activation: hippocampus and choroids
plexus are brain regions at high expression of 5-HT1 and
5-HT2C receptors, respectively, and insulin inhibits chor-
oids plexus 5-HT2C receptors [27]. Additional difficulties
in interpreting our result come from the observation that
increased TSPO has been associated with either tissue/
neuronal damage or repair. Some authors have reported
protective effects of TSPO agonists in experimental dia-
betic neuropathy [28], suggesting, hypothetically, repara-
tive actions of brain TSPO in such a disease.
T h es a m ea sf o rS E R T ,ad e e p e rs t u d yo fT S P Og e n e
and protein expression together the investigation of its
function and drug activities in ob/ob animals by means
of different methodologies, including leptin treatment, is
essential to confirm present results as well as to under-
stand leptin-dependent neuronal trophism, metabolism
and transmission. Another variable to consider is the
different age of mutant animals: in our study, 4 month
old mice were examined, when all symptoms of the
“leptin-lacking syndrome” are present [1], but this does
not exclude the diverse SERT and TSPO expression at
other development or aging stages.
Conclusion
Present results indicate that leptin-lacking mutant mice
have an augmented density of TSPO in the hippocam-
pus and choroids plexus, without changes of SERT pro-
tein number. Central TSPO variations are not paralleled
by changes in periphery (kidney).
Despite limitations due to the small sample of animals
investigated, our study indicates that the obese ob/ob
mouse can be a challenging animal model to elucidate
the mammalian leptin-dependent neuroendocrine-neu-
rosteroid signaling involved in appetite control.
Methods
Materials
[
3H]-paroxetine (specific activity, 24 Ci/mmol) and [
3H]-
PK11195 (specific activity, 69.9 Ci/mmol) were pur-
chased from Perkin-Elmer Life Science (Milan, Italy).
Hyperfilm MP were obtained from Amersham-Pharma-
cia (UK). All other reagents were obtained from normal
commercial sources.
Animals
5 ob/ob (C57BL6V-Lep
ob) and 5 wild-type (C57BL/6J)
adult (age: 15-17 weeks) male mice were obtained from
Harlan (UK) and kept under standard laboratory condi-
tions and feeding: animals were housed two per cage in
saw-dust-lined cages at 22°C under a 12 h light/dark
cycle, with free access to normal diet and tap water. All
experimental procedures were carried out following the
guidelines of the International European ethical stan-
dards for the care and use of laboratory animals (Com-
munity Council Directive 86-609). All protocols were
approved by the Ethical Deontological Committee for
animal experimentation of the University of Pisa.
Sample preparation
Brain and kidney tissues
For experiments, all mice were sacrificed by cervical dis-
location, in the morning, between 8.30-9.30 am, without
modifying diet conditions or access to food. Kidneys
and brains were rapidly removed and treated for mem-
brane preparation and autoradiography. Brains were
taken after removing cerebellum.
Blood collection for plasma chemical analysis
The day of sacrifice, blood was withdrawn by cardiac
puncture of anesthetized mice and collected inside plas-
tic tubes containing lithium-heparin to separate plasma.
Blood was then centrifuged at 2000 g for 3-5 min at
r o o mt e m p e r a t u r eb ym e a n so faM i c r o - C e n t r i f u g e
(Menarini, Italy). Glucose, total cholesterol, High Den-
sity Lipoprotein (HDL), triglycerides, calcium and g-glu-
tamil transpeptidase (gGT) were evaluated by an
automated procedure. Briefly, plasma was automatically
Giannaccini et al. BMC Neuroscience 2011, 12:18
http://www.biomedcentral.com/1471-2202/12/18
Page 5 of 8dispensed on a multi-layered reagent strip, specific for
each dosage, and the resulting colorimetric reaction was
analyzed by the automatic spectrophotometric analyzer
SPOTCHEM SP-4410 (Menarini, Italy).
Blood collection for platelet separation
For separation of platelets used in [
3H]-paroxetine bind-
ing assays, blood, withdrawn as above indicated, was kept
in tubes containing 3% ACD (20 mM acid citric,110 mM
sodium citrate, 5 mM dextrose) and centrifuged at 200 g
for 15 min at room temperature. The supernatant, corre-
sponding to platelet-rich plasma (PRP), was further cen-
trifuged at 10,000 g for 10 min. The resulting pellet was
washed by centrifugation in physiological solution at
10,000 g for 10 min and used for membrane preparation
in [
3H]-paroxetine binding assays (SERT).
Membrane preparation
Preparation of cerebral membranes
To isolate cerebral membrane fractions, after sacrifice,
brains (obtained as above indicated) from animals of
each genotype (n = 4) were weighted, suspended in ice-
cold 1:10 (w/v) 50 mM Tris-HCl, pH 7.4 (Tris-HCl buf-
fer), containing 0.32M sucrose and protease inhibitors
(200 μg/ml bacitracine, 160 μg/ml benzamidine, 20 μg/
ml soy bean trypsin inhibitor), disrupted by means of an
ultra-turrax homogenizer and centrifuged at 1000 g for
5 min at 4°C. Supernatants were then re-centrifuged at
48,000 g for 15 min at 4°C. For [
3H]-paroxetine binding
assay, resulting pellets were suspended in 1:10 volumes
(w/v) of ice-cold Tris-HCl buffer, containing 120 mM
NaCl, 5 mM KCl, protease inhibitors (as above indi-
cated) and treated as previously described [29]. For
[
3H]-PK11195 binding, after the centrifugation step at
48,000 g for 15 min at 4°C, pellets were suspended in
1:10 volumes (w/v) of ice-cold Tris-HCl buffer without
Na/K salts and washed twice in the same buffer by cen-
trifugation at 48,000 g for 15 min at 4°C. Final brain
membrane pellets were stored at -80°C until [
3H]-parox-
etine or [
3H]-PK11195 binding assay.
Preparation of platelet and kidney membranes
For [
3H]-paroxetine binding assay, platelet pellets
(obtained as described previously), were suspended 1:10
(w/v) in 5 mM Tris-HCl buffer containing 5 mM EDTA
and protease inhibitors, homogenized by ultra-turrax
and treated as previously described [30] to obtain mem-
brane-enriched fractions.
Kidney membranes for [
3H]-PK11195 binding assays
were prepared following a procedure slightly modified
from Selleri and co-authors [31]. Briefly, tissue samples
were diluted 1:10 (w/v) in ice-cold 50 mM Tris-HCl, pH
7.4, 0.32M sucrose, 1 mM EDTA (buffer A) containing
protease inhibitors. After homogenization, tissue suspen-
sions were centrifuged at 600 g for 10 min at 4°C. Super-
natants (S1) were collected and kept on ice while pellets
were re-suspended in the same buffer and re-centrifuged
again as above indicated. The resulting supernatants (S2)
were mixed to S1 and centrifuged at 6,500 g for 20 min
at 4°C. Pellets were then suspended in 50 mM Tris-HCl,
pH 7.4 (buffer B) homogenized and centrifuged again at
48,000 g for 10 min at 4°C. Final pellets, resulting from
both procedures, were stored at -80°C until assay.
Protein assay
Total protein concentration was determined in brain,
platelet and kidney membrane preparations according to
the method of Bradford (Bio-Rad), using g-globulins as
the standard.
[
3H]-paroxetine and [
3H]-PK11195 saturation binding
experiments
[
3H]-paroxetine binding (SERT) was carried out as fol-
lows [12]: membranes (50-100 μgp r o t e i n / t u b e )w e r e
incubated with increasing radioligand concentrations
(0.025-5 nM) in 50 mM Tris-HCl buffer, pH 7.4, con-
taining 120 mM NaCl, 5 mM KCl (final volume, 2 ml).
Non specific binding was assessed in the presence of 10
μM fluoxetine, used as the unlabelled displacer. All sam-
ples were assayed in duplicate and incubated 60 min at
22-25°C. TSPO binding was instead appraised as pre-
viously indicated [32]: brain and kidney membranes (25-
100 μg protein/tube) were incubated with increasing
concentrations of [
3H]-PK11195 (0.5-8 nM), in a final
volume of 0.5 ml assay buffer, 50 mM Tris-HCl, pH 7.4.
Non specific binding was assessed in the presence of
1 μM PK11195 as the cold displacer. All samples were
assayed in duplicate and incubated 90 min at 0°C.
In all binding experiments, incubation was halted by
adding 5 ml of cold assay buffer. Samples were immedi-
ately filtered under vacuum through glass fiber GF/C fil-
ters and washed 3 times with 5 ml of assay buffer.
Filters were then placed in pony vials with 4 ml of scin-
tillation cocktail, and radioactivity measured by means
of a b-counter (Packard LS 1600).
[
3H]-paroxetine and [
3H]-PK11195 autoradiography on
brain coronal sections
After animal sacrifice, the brain of ob/ob and WT mice
was rapidly removed, placed in an embedding medium
( O . C . T . ) ,f r o z e ni nl i q u i dn i t r o g e na n ds t o r e da t- 8 5 ° C
until use. Coronal sections (15 μm) at the hippocampal-
hypothalamus levels obtained by cryostat were mounted
onto gelatin-coated slides and stored at -30°C until
assay. The day of assay, sections were allowed to equili-
brate at room temperature for 10 min and pre-incu-
bated in Tris-HCl buffer (50 mM, pH 7.4) for 15 min at
4°C. Sections were then incubated for: 1) 60 min in
Tris-HCl buffer, containing 120 mM NaCl, 5 mM KCl,
with 0.5 nM [
3H]-paroxetine; 2) 90 min at 4°C in Tris-
HCl buffer with 5 nM [
3H]-PK11195 (TSPO). After
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HCl incubation assay buffer at 4°C for 30 sec, then with
distilled water and rapidly dried under a cold air steam.
Non-specific binding was determined by adding to the
incubation solution an excess (10 μM) of unlabelled
fluoxetine (SERT) or PK11195 (TSPO). Autoradiograms
were generated by exposing tissue sections in tritium-
sensitive films for 60 days at -85°C. Films were devel-
o p e di nK o d a kD - 1 9f o r5m i na t1 5 ° Ca n df i x e di n
Kodak rapid Fix. After film exposure, tissue sections
were fixed in 10% formalin and stained with hematoxy-
lin-eosin for anatomical identification.
Data analysis
Equilibrium-saturation binding data, the maximum
binding capacity (Bmax, fmol/mg protein) and the disso-
ciation constant (Kd, nM) were analyzed by means of
the iterative curve-fitting computer program EBDA and
LIGAND [33]. Statistical analysis was performed by
means of Student’s t test (Graph pad version 3-4 pro-
gram, San Diego, CA, USA). To improve visualization of
[
3H]-paroxetine and [
3H]-PK11195 autoradiography, the
gray scale, acquired by a X-ray scanner of autoradio-
graphic films, has been translated into a color scale
using the Image J software (Figure 2).
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